Thus, co-inhibition of TGF-β and HNSCC cells by the combination of CTX + SIS3 (an inhibitor of the TGF-β pathway), delayed tumor progression and lowered tumor volume/weight (HNSCC PDX) (218). Here, TGFB1 is linked to head and neck squamous cell carcinoma.